Aardvark Therapeutics/$AARD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Aardvark Therapeutics
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
- Ticker
- $AARD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 28
- Headquarters
- San Diego, United States
- Website
- aardvarktherapeutics.com
AARD Metrics
BasicAdvanced
$83M
-
-$3.20
-
-
Price and volume
Market cap
$83M
52-week high
$16.60
52-week low
$3.35
Average daily volume
136K
Financial strength
Current ratio
12.629
Quick ratio
11.566
Long term debt to equity
0.004
Total debt to equity
0.009
Profitability
EBITDA (TTM)
-73.913
Management effectiveness
Return on assets (TTM)
-40.38%
Return on equity (TTM)
-66.02%
Valuation
Price to book
1.11
Price to tangible book (TTM)
1.11
Price to free cash flow (TTM)
-1.188
Free cash flow yield (TTM)
-84.21%
Free cash flow per share (TTM)
-3.183
Growth
Earnings per share change (TTM)
-6.01%
What the Analysts think about AARD
Analyst ratings (Buy, Hold, Sell) for Aardvark Therapeutics stock.
Analyst projections of the future price of Aardvark Therapeutics stock.
AARD Financial Performance
Revenues and expenses
AARD Earnings Performance
Company profitability
Upcoming events
No upcoming events
AARD News
AllArticlesVideos
AARD DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD
Newsfile Corp6 days ago
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
Business Wire6 days ago
AARD DEADLINE TOMORROW: ROSEN, REGARDED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD
Newsfile Corp1 week ago
Funds containing AARD
AllUSDGBP
Fund name | Fund size | $AARD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.